Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26‐week data of the FACTS II survey by Vavricka, Stephan R., Schoepfer, Alain M., Bansky, Georg, Binek, Janek, Felley, Christian, Geyer, Martin, Manz, Michael, Rogler, Gerhard, de Saussure, Philippe, Sauter, Bernhard, Scharl, Michael, Seibold, Frank, Straumann, Alex, Michetti, Pierre

Get full text